Outlook Therapeutics® to Participate in the Virtual Investor Closing Bell Series
Outlook Therapeutics (Nasdaq: OTLK), a biopharmaceutical company, announced its participation in the Virtual Investor Closing Bell Series. Russell Trenary, President and CEO, will present on Thursday, September 19, 2024, at 4:00 PM ET. The event will include a corporate overview, business outlook, and a live Q&A session.
Notably, Outlook Therapeutics recently achieved regulatory approval in the European Union and the United Kingdom for the first authorized use of an ophthalmic formulation of bevacizumab to treat wet age-related macular degeneration (wet AMD). This milestone highlights the company's progress in the ophthalmology field.
Investors can access the live video webcast on the company's website, with a replay available for 90 days post-event.
Outlook Therapeutics (Nasdaq: OTLK), un'azienda biofarmaceutica, ha annunciato la sua partecipazione alla Virtual Investor Closing Bell Series. Russell Trenary, Presidente e CEO, presenterà giovedì 19 settembre 2024, alle 16:00 ET. L'evento includerà una panoramica aziendale, le prospettive commerciali e una sessione di domande e risposte dal vivo.
È importante notare che Outlook Therapeutics ha recentemente ottenuto l'approvazione regolatoria nell'Unione Europea e nel Regno Unito per il primo uso autorizzato di una formulazione oftalmica di bevacizumab per trattare la degenerazione maculare legata all'età umida (wet AMD). Questo traguardo evidenzia i progressi della compagnia nel campo dell'oftalmologia.
Gli investitori possono accedere al webcast video in diretta sul sito web dell'azienda, con una registrazione disponibile per 90 giorni dopo l'evento.
Outlook Therapeutics (Nasdaq: OTLK), una compañía biofarmacéutica, anunció su participación en la serie Virtual Investor Closing Bell. Russell Trenary, Presidente y CEO, presentará el jueves 19 de septiembre de 2024, a las 4:00 PM ET. El evento incluirá una descripción general de la empresa, perspectiva comercial y una sesión de preguntas y respuestas en vivo.
Es notable que Outlook Therapeutics recientemente logró la aprobación regulatoria en la Unión Europea y el Reino Unido para el primer uso autorizado de una formulación oftálmica de bevacizumab para tratar la degeneración macular relacionada con la edad húmeda (wet AMD). Este hito destaca el avance de la empresa en el campo de la oftalmología.
Los inversores pueden acceder al webcast de video en vivo en el sitio web de la compañía, con una repetición disponible durante 90 días después del evento.
아웃룩 테라퓨틱스 (Nasdaq: OTLK), 생명공학 제약 회사가 가상 투자 마감 종 시리즈에 참여한다고 발표했습니다. 러셀 트레너, 사장 겸 CEO가 2024년 9월 19일 목요일 오후 4:00 ET에 발표할 예정입니다. 이 행사에서는 기업 개요, 비즈니스 전망 및 라이브 질의응답 세션이 포함됩니다.
특히 아웃룩 테라퓨틱스는 유럽연합 및 영국에서의 규제 승인을 최근에 획득했으며, 습성 노년성 황반변성 (wet AMD) 치료를 위해 베바시주맙의 안과용 제형을 최초로 승인받았습니다. 이 이정표는 안과 분야에서 회사의 발전을 강조합니다.
투자자들은 회사 웹사이트에서 실시간 비디오 웹캐스트에 접속할 수 있으며, 행사 후 90일 동안 재생이 가능합니다.
Outlook Therapeutics (Nasdaq: OTLK), une entreprise biopharmaceutique, a annoncé sa participation à la série Virtual Investor Closing Bell. Russell Trenary, Président et CEO, présentera le jeudi 19 septembre 2024, à 16h00 ET. L'événement comprendra un aperçu de l'entreprise, un aperçu commercial et une séance de questions-réponses en direct.
Il est notable qu'Outlook Therapeutics a récemment obtenu l'approbation réglementaire dans l'Union européenne et au Royaume-Uni pour le premier usage autorisé d'une formulation ophtalmique de bévacizumab pour traiter la dégénérescence maculaire liée à l'âge humide (wet AMD). Ce jalon met en évidence les progrès de la société dans le domaine de l'ophtalmologie.
Les investisseurs peuvent accéder au webinaire vidéo en direct sur le site Internet de l'entreprise, avec une rediffusion disponible pendant 90 jours après l'événement.
Outlook Therapeutics (Nasdaq: OTLK), ein biopharmazeutisches Unternehmen, gab seine Teilnahme an der Virtual Investor Closing Bell Series bekannt. Russell Trenary, Präsident und CEO, wird am Donnerstag, den 19. September 2024, um 16:00 Uhr ET präsentieren. Die Veranstaltung umfasst eine Unternehmensübersicht, Geschäftsausblick und eine Live-Frage-und-Antwort-Runde.
Bemerkenswert ist, dass Outlook Therapeutics kürzlich die regulatorische Genehmigung in der Europäischen Union und im Vereinigten Königreich für die erste genehmigte Anwendung einer oftalmologischen Formulierung von Bevacizumab zur Behandlung von nasser altersbedingter Makuladegeneration (wet AMD) erhalten hat. Dieser Meilenstein verdeutlicht den Fortschritt des Unternehmens im Bereich der Augenheilkunde.
Investoren können auf die live Videoübertragung auf der Website des Unternehmens zugreifen, wobei eine Wiederholung 90 Tage nach der Veranstaltung verfügbar ist.
- None.
- None.
Live video webcast with Russell Trenary, President and CEO of Outlook Therapeutics on Thursday, September 19th at 4:00 PM ET
ISELIN, N.J., Sept. 16, 2024 (GLOBE NEWSWIRE) -- Outlook Therapeutics, Inc. (Nasdaq: OTLK), a biopharmaceutical company that achieved regulatory approval in the European Union and the United Kingdom earlier this year for the first authorized use of an ophthalmic formulation of bevacizumab for the treatment of wet age-related macular degeneration (wet AMD), today announced that Russell Trenary, President and CEO of Outlook Therapeutics will participate in the Virtual Investor Closing Bell Series on Thursday, September 19, 2024 at 4:00 PM ET.
As part of the event, Mr. Trenary will provide a corporate overview and business outlook. In addition to the prepared remarks, there will be a live question and answer session. Mr. Trenary will answer as many questions as possible in the time allowed.
A live video webcast of the presentation will be available on the Events page in the Investors section of the Company’s website (outlooktherapeutics.com). The webcast replay will be archived for 90 days following the event.
About Outlook Therapeutics, Inc.
Outlook Therapeutics is a biopharmaceutical company focused on the development and commercialization of ONS-5010/LYTENAVA™ (bevacizumab-vikg; bevacizumab gamma), for the treatment of retina diseases, including wet AMD. LYTENAVA™ (bevacizumab gamma) is the first ophthalmic formulation of bevacizumab to receive European Commission and MHRA Marketing Authorization for the treatment of wet AMD. Outlook Therapeutics is working to initiate its commercial launch of LYTENAVA™ (bevacizumab gamma) in the EU and the UK as a treatment for wet AMD, expected in the first half of calendar 2025. In the United States, ONS-5010/LYTENAVA™ is investigational, is being evaluated in an ongoing non-inferiority study for the treatment of wet AMD, and if successful, the data may be sufficient for Outlook to resubmit a BLA to the FDA in the United States. If approved in the United States, ONS-5010/LYTENAVA™, would be the first approved ophthalmic formulation of bevacizumab for use in retinal indications, including wet AMD.
Investor Inquiries:
Jenene Thomas
Chief Executive Officer
JTC Team, LLC
T: 833.475.8247
OTLK@jtcir.com
FAQ
When is Outlook Therapeutics (OTLK) participating in the Virtual Investor Closing Bell Series?
What recent regulatory approvals has Outlook Therapeutics (OTLK) received?
Who will be presenting at the Virtual Investor Closing Bell Series for Outlook Therapeutics (OTLK)?
What will be discussed during Outlook Therapeutics' (OTLK) presentation at the Virtual Investor Closing Bell Series?
How can investors access Outlook Therapeutics' (OTLK) presentation at the Virtual Investor Closing Bell Series?
